BioBlast Pharma (ORPN) Tops Q2 EPS by 5c

BioBlast Pharma (Nasdaq: ORPN) reported Q2 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27).

Cash and cash equivalents (including short-term bank deposits) totaled $15.7 million at June 30, 2016, compared with $19.3 million at December 31, 2015.

For earnings history and earnings-related data on BioBlast Pharma (ORPN) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance